Rare diseases
Investigational molecules
Locations
A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.
ItalyN1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
ItalyStudy of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment
ItalyA study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction
ItalyA study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function
ItalyStudy of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer
ItalyA study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy
ItalyA study comparing prasinezumab with placebo for people with early-stage Parkinson's disease
ItalyStudy of oral cladribine compared to placebo for patients with generalized myasthenia gravis
ItalyA study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene
ItalyA study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy
ItalyA study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
